Monopar Therapeutics Stock Performance
| MNPR Stock | USD 55.46 3.78 6.38% |
The company secures a Beta (Market Risk) of 0.29, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Monopar Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Monopar Therapeutics is expected to be smaller as well. At this point, Monopar Therapeutics has a negative expected return of -0.34%. Please make sure to verify Monopar Therapeutics' information ratio and kurtosis , to decide if Monopar Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Monopar Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (0.25) | Five Day Return 2.28 | Year To Date Return (10.26) | Ten Year Return (55.29) | All Time Return (55.29) |
Last Split Factor 1:5 | Last Split Date 2024-08-13 |
1 | Acquisition by Cittadine Andrew of 43445 shares of Monopar Therapeutics at 31.7 subject to Rule 16b-3 | 11/21/2025 |
2 | Acquisition by Klausner Arthur J of 7710 shares of Monopar Therapeutics subject to Rule 16b-3 | 12/16/2025 |
3 | Monopar Therapeutics CFO Quan Anh Vu Acquires 1,500 Shares | 12/29/2025 |
4 | Disposition of 4326 shares by Cittadine Andrew of Monopar Therapeutics subject to Rule 16b-3 | 12/31/2025 |
5 | Will Monopar Therapeutics Inc. stock keep outperforming rivals - Entry Point Low Risk Investment Opportunities - ulpravda.ru | 01/08/2026 |
6 | Acquisition by Cittadine Andrew of 1791 shares of Monopar Therapeutics subject to Rule 16b-3 | 01/09/2026 |
7 | Monopar Therapeutics Inc. Given Average Rating of Buy by Brokerages | 01/14/2026 |
8 | JonesTrading Maintains Monopar Therapeutics With Buy Rating, Maintains Target Price 130 - | 01/23/2026 |
9 | BTIG Reiterates Buy Rating on Monopar Therapeutics MNPR Stock News - GuruFocus | 02/02/2026 |
| Begin Period Cash Flow | 7.3 M | |
| Total Cashflows From Investing Activities | -14.3 M |
Monopar Therapeutics Relative Risk vs. Return Landscape
If you would invest 7,643 in Monopar Therapeutics on November 15, 2025 and sell it today you would lose (1,719) from holding Monopar Therapeutics or give up 22.49% of portfolio value over 90 days. Monopar Therapeutics is currently does not generate positive expected returns and assumes 4.0676% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Monopar, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Monopar Therapeutics Target Price Odds to finish over Current Price
The tendency of Monopar Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 55.46 | 90 days | 55.46 | roughly 97.0 |
Based on a normal probability distribution, the odds of Monopar Therapeutics to move above the current price in 90 days from now is roughly 97.0 (This Monopar Therapeutics probability density function shows the probability of Monopar Stock to fall within a particular range of prices over 90 days) .
Monopar Therapeutics Price Density |
| Price |
Predictive Modules for Monopar Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Monopar Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Monopar Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Monopar Therapeutics is not an exception. The market had few large corrections towards the Monopar Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Monopar Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Monopar Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.42 | |
β | Beta against Dow Jones | 0.29 | |
σ | Overall volatility | 9.05 | |
Ir | Information ratio | -0.11 |
Monopar Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Monopar Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Monopar Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Monopar Therapeutics generated a negative expected return over the last 90 days | |
| Monopar Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (15.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Monopar Therapeutics currently holds about 16.46 M in cash with (6.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
| Monopar Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: BTIG Reiterates Buy Rating on Monopar Therapeutics MNPR Stock News - GuruFocus |
Monopar Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Monopar Stock often depends not only on the future outlook of the current and potential Monopar Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Monopar Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 11.5 M | |
| Cash And Short Term Investments | 60.2 M |
Monopar Therapeutics Fundamentals Growth
Monopar Stock prices reflect investors' perceptions of the future prospects and financial health of Monopar Therapeutics, and Monopar Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Monopar Stock performance.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | 253.27 M | ||||
| Shares Outstanding | 6.68 M | ||||
| Price To Earning | (35.82) X | ||||
| Price To Book | 2.80 X | ||||
| EBITDA | (16.16 M) | ||||
| Net Income | (15.59 M) | ||||
| Cash And Equivalents | 16.46 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 5.25 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.61 X | ||||
| Book Value Per Share | 21.25 X | ||||
| Cash Flow From Operations | (6.4 M) | ||||
| Earnings Per Share | (3.96) X | ||||
| Market Capitalization | 395.88 M | ||||
| Total Asset | 60.29 M | ||||
| Retained Earnings | (75.79 M) | ||||
| Working Capital | 55.04 M | ||||
| Current Asset | 11.55 M | ||||
| Current Liabilities | 598.26 K | ||||
About Monopar Therapeutics Performance
Assessing Monopar Therapeutics' fundamental ratios provides investors with valuable insights into Monopar Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Monopar Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.34) | (0.35) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.33) | (0.34) |
Things to note about Monopar Therapeutics performance evaluation
Checking the ongoing alerts about Monopar Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Monopar Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Monopar Therapeutics generated a negative expected return over the last 90 days | |
| Monopar Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (15.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Monopar Therapeutics currently holds about 16.46 M in cash with (6.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
| Monopar Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: BTIG Reiterates Buy Rating on Monopar Therapeutics MNPR Stock News - GuruFocus |
- Analyzing Monopar Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Monopar Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Monopar Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Monopar Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Monopar Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Monopar Therapeutics' stock. These opinions can provide insight into Monopar Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.